All In Biotech

Drug Trial Radar · NCT07357675

A Clinical Trial To Investigate The Effect Of EA-230 On Hospital Length Of Stay In Patients With Coronary Artery Disease (CAD) Undergoing Coronary Artery Bypass Grafting (CABG) Surgery.

A Clinical Trial To Investigate The Effect Of EA-230 On Hospital Length of Stay In Patients With Coronary Artery Disease (CAD) Undergoing Coronary Artery Bypass Grafting (CABG) Surgery.

Last checked: Nov 19, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 300 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

300

Planned (sponsor's estimate)

Start

Oct 29, 2026

Primary completion

Oct 1, 2027

Study completion Dec 1, 2027

Sponsor

Lead sponsor
EBI Anti Sepsis BVIndustry
Sponsor type
Industry
Collaborators
CR2O B.V.
First posted
Jan 22, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

EA-230 is a new therapy that may help people recover faster and have fewer problems after bypass surgery. In an earlier clinical trial, participants who received EA-230 during Coronary Artery Bypass surgery stayed in the Intensive Care Unit (ICU) and the hospital for a shorter time and had fewer serious complications, compared to those who received a placebo (an inactive therapy). The use of EA-230 was safe and well tolerated. This trial will test EA-230 in more participants to see if it really works and is safe to use in the future. This is a Phase III trial. It will take place in multiple locations and will follow a double-blind, randomized, placebo-controlled clinical design, meaning neither doctors nor participants will know whether they receive EA-230 or placebo during the trial. Assignment to EA-230 or placebo occurs by chance, like throwing dice. The total duration of the trial, including medical check-ups, will be approximately 71 days. There is a total of 10 visits, including a screening-, a pre-operative-, and 2 remote visits. 7 of these visits are during your stay at the hospital.

Conditions

  • Coronary Artery Disease (CAD)
  • Coronary Artery Bypass Graft Surgery(CABG)

Interventions

  • EA-230 90mg/kg/hourDrug

    Intravenous administration of 90mg/kg per hour for 4 hours.

  • PlaceboDrug

    Placebo administered intravenously for 4 hours

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Required postoperative hospital length of stayTime frame: Up to 28 days

Locations

6 sites in 4 countries. Site status is shown where the registry gives one.

  • MAYO clinic

    Rochester, Minnesota · Not yet recruiting

  • UPMC

    Pittsburgh, Pennsylvania · Not yet recruiting

  • UZ Gent

    Ghent, Belgium · Recruiting

  • Medisch Spectrum Twente

    Enschede, Netherlands · Recruiting

  • RadboudUMC

    Nijmegen, Netherlands · Recruiting

  • St Thomas' Hospital

    London, United Kingdom · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.